Piramal deal will give Abbott India size Piramal, who is the chairman of Piramal Healthcare, said “the valuation of about nine times shows the. It took four hours for Ajay Piramal to negotiate a whopping $ billion valuation for his generics business with Abbott. Just how did he pull it off. Abbott to pay $ billion for unit of India’s Piramal Disagreements over valuation have prevented more deals from getting done. Abbott.

Author: Malataxe Taubei
Country: Slovenia
Language: English (Spanish)
Genre: Sex
Published (Last): 24 April 2006
Pages: 57
PDF File Size: 6.86 Mb
ePub File Size: 9.43 Mb
ISBN: 143-8-73893-190-3
Downloads: 32417
Price: Free* [*Free Regsitration Required]
Uploader: Arataur

Shares in Mumbai-based Piramal closed Mr Piramal did not say what he will do with the remaining money. Of its brands sold on Friday, piranal least 48 have sales of more than Rs 10 crore a year and are marketed by a sales force of 4, who reach more than 2. Abbott and other Big Pharma companies face the twin challenges of slow growth in the developed markets and maturing product pipelines that are getting harder to replenish with newer, blockbuster drugs, according deao Chaudhuri.

All the same, the West continues to dominate pharmaceutical innovation, and companies in India and other emerging markets could play a supportive role, according to Danzon.

Mumbai-based Piramal said it would consider paying a special dividend and valuwtion use deal proceeds to invest in its remaining businesses abboty pay down debt. Its other businesses include third-party manufacturing and pathology laboratories. Danzon adds that the emerging business plan for generics companies is essentially around selling to pharmacists, not physicians. On top of that, India is a growing market.

Danzon points to Piramxl. Increased funding expands the scope for drug research, but that alone is not enough; other pieces have to fall in place, Piramal notes. Innovation From Book to Bank: Read more on Piramal. The stigma of selling—that has been holding back promoters of Indian pharmaceutical companies—is gone after two large lucrative deals in the sector, said an investment banker who asked not to be named.


This will alert our moderators to take action Name Reason for reporting: Food and Drug Administration said in February Ranbaxy sold misbranded or adulterated drugs in the United States, its largest market, having earlier banned imports of over 30 generic drugs from the firm. By comparison, Cipla trades at about 4. Drag according to your convenience.

BOthe U. Will be displayed Will not be displayed Will be displayed. Unlike valustion a promoter stake sale, in this case the money will some to the company. Unlike other pharmaceutical acquisitions that have been targeted at buying Indian generic capacity to service Western and emerging markets, the Abbott-Piramal deal is primarily focused on the domestic market, according to Mumbai-based business magazine Business Dfal.

BOis booming as governments battle rising healthcare costs. There are a limited number of Indian generics companies that are pirmaal, and there might be considerable competition for them. That is one reason pharmaceutical multinationals are doing deals with the relatively small number of well established Indian companies that have met international standards in manufacturing. The collaboration includes medicines for pain, cancer and cardiovascular, neurological and respiratory diseases, with product launches beginning in You have to create a whole organization, and that takes time.

Get instant notifications from Economic Times Allow Not now You can switch off notifications anytime using browser settings.

Yet, Piramal investors are disappointed. Get instant notifications from Economic Times Allow Not now.

Seven years after Piramal deal, Abbott way off revenue target

Globalization is not just for manufacturers. But investors remain disappointed in the absence of an open offer. Additional Reading Management Finding the Virtue in Private Equity Firms Many view private equity firms as villainous actors intent on the singular goal of profit. There is intense speculation that Mr Piramal will buy companies in some of these segments. The materialisation of this deal will also encourage buyers loosen their wallets. L as possible buyers.


Several other deals occurred over the past one year. Oiramalas global drugmakers look to boost their presence in emerging markets. A key differentiator here is that unlike in the U.

Forbes India Magazine – Print

The earlier regime recognized patents on pharmaceutical processes but not on pharmaceutical products, allowing companies to reverse-engineer copies of the branded and patented drugs of western companies. Choose your pigamal below and click on the Report button. As a global MNC, Abbott does. Some said prices of medicines will go up. Wharton professor of healthcare management Patricia Danzon agrees. To see your saved stories, click on link hightlighted in bold.

It is not so much a concern about the downside, but about how we maximize the opportunity. These other players are not even interested in doing that. Fill in your details: Sumeet ChatterjeeBharghavi Nagaraju.

It is paying roughly 8. But that is also changing, she says. Chaudhuri acknowledges those new realities, but with a patriotic tinge.

Abbott to pay $ billion for unit of India’s Piramal | Reuters

Sign up for the weekly Knowledge Wharton e-mail newsletter, offering business leaders cutting-edge research and ideas from Wharton faculty and other experts. NIFTY 50 10, However, companies like Abbott vxluation others getting into new generic drug markets must be watchful of the changing lay of the land there as well, according to Danzon.

Are you a Business Owner?